Frontlight ResearchEarly access
Active, not recruitingPhase 1/2
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
Key facts
- Who runs it
- JCR Pharmaceuticals Co., Ltd.
- Where
- Japan4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 1/2
- People taking part
- 10 people, planned
- Started
- 5 Nov 2024
- Expected to end
- 30 Apr 2030
- Type of study
- Interventional
- Treatments tested
- JR-446
- Record updated
- 1 October 2026
Who can take part
- Age
- Up to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Chronological age of <18 years
- Confirmed diagnosis of MPS IIIB
Who cannot take part
- Prior experience to gene therapy or HSCT with successful engraftment
- Past use of another investigational drug or product in last 4 months or 5 half-lives (whichever is longer) before signing ICF
- Past use of Genistein or Kineret (anakinra) within 4 months before signing ICF
- Serious drug allergy or hypersensitivity
- History of bleeding disorder or current use of medications that, in the opinion of the investigator, place them at risk of bleeding following lumbar puncture; The above information is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial
- Current participation in a clinical trial or past participation (within 30 days of enrolment into this study) in a study involving invasive procedures
- Contraindication for lumbar puncture or MRI
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A Phase I/ II, open-label study, designed to evaluate the safety and explore efficacy of the study drug in development for the treatment of MPS IIIB patients.
The group in the trial
- JR-446Treatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 1 October 2026